Birgit Sawitzki
University Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
In a subset of children and adolescents, SARS-CoV-2 infection induces a severe acute hyperinflammatory shock 1 termed multisystem inflammatory syndrome in children (MIS-C) at four to eight weeks after infection. MIS-C is characterized by a specific T cell expansion 2 and systemic hyperinflammation 3 . The pathogenesis of MIS-C remains largely unknown. Here we show that acute MIS-C is characterized by impaired reactivation of virus-reactive memory T cells, which depends on increased serum levels of the cytokine TGFβ resembling those that occur during severe COVID-19 (refs. 4,5 ). This functional impairment in T cell reactivity is accompanied by the presence of TGFβ-response signatures in T cells, B cells and monocytes along with reduced antigen-presentation capabilities of monocytes, and can be reversed by blocking TGFβ. Furthermore, T cell receptor repertoires of patients with MIS-C exhibit expansion of T cells expressing TCRVβ21.3, resembling Epstein–Barr virus (EBV)-reactive T cell clones capable of eliminating EBV-infected B cells. Additionally, serum TGFβ in patients with MIS-C can trigger EBV reactivation, which is reversible with TGFβ blockade. Clinically, the TGFβ-induced defect in T cell reactivity correlates with a higher EBV seroprevalence in patients with MIS-C compared with age-matched controls, along with the occurrence of EBV reactivation. Our findings establish a connection between SARS-CoV-2 infection and COVID-19 sequelae in children, in which impaired T cell cytotoxicity triggered by TGFβ overproduction leads to EBV reactivation and subsequent hyperinflammation.
Year:
2025
Background The majority of patients recovers from severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) coronavirus disease 2019 (COVID-19) without obvious sequelae, but a significant proportion suffers long-term consequences which have been termed post COVID syndrome (PCS). Despite a wide range of considerations on treatment options in PCS and a significant number of trials initiated, only very few results from randomized controlled trials are currently available. In conclusion, there is an evident medical need to identify treatments for patients with PCS. Methods The primary objective of the platform trial RAPID is to assess the impact of different PCS treatments on the overall physical function of patients. Designed as a master protocol, RAPID contains all information that is generic to this adaptive platform trial. Current and future study treatments are specified in intervention-specific appendices (ISA). The first ISA, RAPID_REVIVE is presented in this manuscript. General sections of the master protocol are named as such. RAPID_REVIVE is a double-blind, placebo-controlled, phase II clinical trial evaluating antiviral PCS treatment with vidofludimus calcium (IMU-838). Patients are randomized at a 1:1 ratio to 45 mg/day vidofludimus calcium (22.5 mg for the first 7 days) or placebo during an initialization phase and thereafter using a response-adaptive randomization procedure. The trial includes a screening period of 7 days, a double-blind treatment period of 56 days and a follow-up period of 28 days. The primary outcome is the intra-patient change in physical function measured by the Short Form-36 Physical Function (SF-36-PF) from baseline to day 56. Secondary endpoints include mental and physical health, intensity of fatigue, severity of mental disorder symptoms, and cognitive function. Discussion PCS is a major problem for global health care and the identification of treatment options is urgently needed. Currently, PCS patients are in a situation without evidence-based treatment options, and quality of life, and often mental health are significantly impaired. The purpose of RAPID is to establish an adaptive platform trial protocol which will concert and quicken clinical trials to evaluate the efficacy and safety of different potential treatments for PCS with the aim to expand the very limited evidence base for the treatment of PCS. Trial registration EU Clinical Trials Register (CTIS) ID: 2024–511628-16–00 (RAPID_REVIVE). Registered on 18.03.2024.
Year:
2025
Immune evasion by escape mutations subverts immunity against SARS‐CoV‐2. A role of pan‐coronavirus immunity for more durable protection is being discussed, but has remained understudied. We here investigated the effects of age, mutations, and homo‐/heterologous vaccination regimens on the dominant pan‐coronavirus‐specific cellular and humoral epitope iCope after SARS‐CoV‐2 infection and vaccination in detail. In older individuals, the quantitatively and qualitatively reduced iCope‐reactive CD4 + T cell responses with narrow TCR repertoires could not be enhanced by vaccination and were further compromised by emerging spike mutations. In contrast, pan‐coronavirus‐reactive humoral immunity was affected only by mutations and not by age. Our results reveal a distinct deficiency of the dichotomous layer of pan‐coronavirus immunity in the older, critical for long‐term protection against SARS‐CoV‐2 variants.
Year:
2025
Year:
2025
Myocarditis, characterized by inflammatory cell infiltration, can have multiple etiologies, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection or, rarely, mRNA-based coronavirus disease 2019 (COVID-19) vaccination. The underlying cellular and molecular mechanisms remain poorly understood. In this study, we performed single-nucleus RNA sequencing on left ventricular endomyocardial biopsies from patients with myocarditis unrelated to COVID-19 (Non-COVID-19), after SARS-CoV-2 infection (Post-COVID-19) and after COVID-19 vaccination (Post-Vaccination). We identified distinct cytokine expression patterns, with interferon-γ playing a key role in Post-COVID-19, and upregulated IL16 and IL18 expression serving as a hallmark of Post-Vaccination myocarditis. Although myeloid responses were similar across all groups, the Post-Vaccination group showed a higher proportion of CD4 + T cells, and the Post-COVID-19 group exhibited an expansion of cytotoxic CD8 + T and natural killer cells. Endothelial cells showed gene expression changes indicative of vascular barrier dysfunction in the Post-COVID-19 group and ongoing angiogenesis across all groups. These findings highlight shared and distinct mechanisms driving myocarditis in patients with and without a history of SARS-CoV-2 infection or vaccination.
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (45)
Franziska Sotzny
Charité - Universitätsmedizin Berlin
Anja E. Hauser
-
Antigoni Triantafyllopoulou
Prof. Dr.
Charité - Universitätsmedizin Berlin
Florian Kern
Foundation Chair of Immunology
Brighton and Sussex Medical School
Sebastian Wisniewski
Charité Universitätsmedizin Berlin - Campus Virchow-Klinikum
Laura Kim
Charité - Universitätsmedizin Berlin
Kristen Radford
The University of Queensland
THI HOANG OANH NGUYEN
University of Melbourne
Wolfram Doehner
Charité - Universitätsmedizin Berlin
Petra Knaus
Freie Universität Berlin
Julia K. Polansky
Prof, Group leader
Charité - Universitätsmedizin Berlin
Carolien van de Sandt
Team Leader/Senior Research Fellow
Murdoch Childrens Research Institute
Michael Mülleder
Head
Charité - Universitätsmedizin Berlin
Rob C.I. Wüst
University of Amsterdam
Mir-Farzin Mashreghi
Group Leader
Deutsches Rheuma-Forschungszentrum Berlin
Christian Meisel
Charité - Universitätsmedizin Berlin
Julian Braun
Charité - Universitätsmedizin Berlin
Christian H. Bucher
Charité - Universitätsmedizin Berlin
Lucie Loyal
Charité - Universitätsmedizin Berlin
Pinkus Tober-Lau
Charité - Universitätsmedizin Berlin
Michael Schmueck-Henneresse
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Florian Kurth
Bernhard-Nocht-Institut für Tropenmedizin
David Game
Consultant Nephrologist and Honorary Senior Lecturer
-
Roman David Bülow
Professor (W1) for Digital Pathology
RWTH Aachen University
Tim Friede
Professor
Universitätsmedizin Göttingen
Leila Amini
Charité - Universitätsmedizin Berlin
Frank Konietschke
Charité - Universitätsmedizin Berlin
Judith Bellmann-Strobl
Charité - Universitätsmedizin Berlin
Sven Geißler
Professor of the Biology of Musculoskeletal Regeneration
Charité - Universitätsmedizin Berlin
Karl Johan Tronstad
Professor in biochemistry and molecular biology
University of Bergen
Marcus Mall
Charité - Universitätsmedizin Berlin
Stefan Frischbutter
Head of Basic Science
Charité Universitätsmedizin Berlin Campus Benjamin Franklin
David Hillus
Charité - Universitätsmedizin Berlin
Simon Haas
Group leader
Deutsches Krebsforschungszentrum
Delphine Kervella
Université de Nantes
Sandy Kroh
Charité - Universitätsmedizin Berlin
Jonathan Seidman
Professor
Harvard University
Benedikt Obermayer
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Anna C Aschenbrenner
Group Leader [W2 equivalent, tenured]
Deutsches Zentrum für Neurodegenerative Erkrankungen
Kathryn Hoffmann
Head of the Department, Univ.-Prof
Medical University of Vienna
Jobst F. Roehmel
-
Lisa Ehlers
Charité - Universitätsmedizin Berlin
Frederik Heinrich
Deutsches Rheuma-Forschungszentrum Berlin
Carmen Scheibenbogen
Charité - Universitätsmedizin Berlin
Britt Wildemann
Jena University Hospital
Make your next move.
Prepare your application
Review drafts before you send them.